Nanoparticles News and Research

RSS

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

Titanium dioxide (TiO2) nanoparticles, found in everything from cosmetics to sunscreen to paint to vitamins, caused systemic genetic damage in mice, according to a comprehensive study conducted by researchers at UCLA's Jonsson Comprehensive Cancer Center.

17 Nov 2009

New technology may lessen health and environmental concerns about nanotechnology industry

In an advance that could help ease health and environmental concerns about the emerging nanotechnology industry, scientists are reporting development of technology for changing the behavior of nanoparticles in municipal sewage treatment plants - their main gateway into the environment. Their study will be published online November 12 in ACS' journal Environmental Science & Technology.

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.

12 Nov 2009

Future for magnetic nanoparticles appears even brighter

Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade.

6 Nov 2009

Nanoparticles may cause DNA damage across a cellular barrier

Scientists have shown in the laboratory that metal nanoparticles damaged the DNA in cells on the other side of a cellular barrier. The nanoparticles did not cause the damage by passing through the barrier, but generated signalling molecules within the barrier cells that were then transmitted to cause damage in cells the other side of the barrier.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007.

4 Nov 2009

NIH grant to NC State researchers to study how nanomaterials interact with biological systems

Tiny, engineered nanomaterials can already be found in many consumer products, and have been hailed as having widespread future uses in areas ranging from medicine to industrial processes. However, little is known about what happens if these nanomaterials get into your body - where do they go? NC State researchers are working to answer that question under a grant from the National Institutes of Health (NIH).

4 Nov 2009

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma.

4 Nov 2009

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

4 Nov 2009

AAPS workshop on drug release methodologies

AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.

29 Oct 2009

Nanoparticles from antibacterial textiles could harm fish and other wildlife

Scientists in Switzerland are reporting results of one of the first studies on the release of silver nanoparticles from laundering those anti-odor, anti-bacterial socks now on the market. Their findings, scheduled for the Nov. 1 issue of ACS' journal Environmental Science & Technology, may suggest ways that manufacturers and consumers can minimize the release of these particles to the environment, where they could harm fish and other wildlife.

29 Oct 2009

NCI grant to conduct innovative cancer research

A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.

28 Oct 2009

University researchers inject 'nanowires' in rat brains

The biological safety of nanotechnology, in other words, how the body reacts to nanoparticles, is a hot topic. Researchers at Lund University in Sweden have managed for the first time to carry out successful experiments involving the injection of so-called 'nanowires.'

23 Oct 2009

Gates Foundation awards Vanderbilt University $100,000 for developing a malaria diagnostic test

Vanderbilt University announced Oct. 21 that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Associate Professor of Chemistry David Wright and Professor of Biomedical Engineering Rick Haselton, titled "Coffee Ring Stain Diagnostics for Malaria."

22 Oct 2009

Manhattan Scientifics enters into a non-binding LOI with Edward R. Flynn

Manhattan Scientifics announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn’s patents and IP in the emerging field of nanomedicine.

21 Oct 2009

Cancer Therapeutics and Nanotherapies sign letter of intent

Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.

19 Oct 2009

Current safety equipment may not be adequate for nanoprotection

Writing in a forthcoming issue of the International Journal of Nanotechnology, Canadian engineers suggest that research is needed into the risks associated with the growing field of nanotechnology manufacture so that appropriate protective equipment can be developed urgently.

14 Oct 2009

Nanoparticles News and Research

Titanium dioxide nanoparticles causes systemic genetic damage in mice, say researchers

New technology may lessen health and environmental concerns about nanotechnology industry

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

New Cat B 750 FAST imaging agent launched by VisEn Medical

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Future for magnetic nanoparticles appears even brighter

Nanoparticles may cause DNA damage across a cellular barrier

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

NIH grant to NC State researchers to study how nanomaterials interact with biological systems

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

AAPS workshop on drug release methodologies

Nanoparticles from antibacterial textiles could harm fish and other wildlife

NCI grant to conduct innovative cancer research

University researchers inject 'nanowires' in rat brains

Gates Foundation awards Vanderbilt University $100,000 for developing a malaria diagnostic test

Manhattan Scientifics enters into a non-binding LOI with Edward R. Flynn

Cancer Therapeutics and Nanotherapies sign letter of intent

Current safety equipment may not be adequate for nanoprotection

How to solve the hidden bottleneck in lipid nanoparticle development eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News